secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071382
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics Q1 net loss $10.4M; Phase 3 LEVEL enrollment on track for year-end 2025
--------------------------------------------------------------------------------

- Net loss $10.4M in Q1 2025 vs $3.8M in Q1 2024; company is a development-stage biotech with no revenue.
- Cash and equivalents $111.4M as of March 31, 2025; raised ~$25M gross proceeds from private placement in March 2025.
- Phase 3 LEVEL study enrollment of 230 patients in PH-HFpEF targeted for completion around year-end 2025; topline data mid-2026.
- Initiation of second registrational Phase 3 study (LEVEL-2) for TNX-103 expected in 2025.
- R&D expense $5.7M (up from $2.7M) and G&A $5.7M (up from $1.2M) due to trial costs and stock-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000095017025071382/0000950170-25-071382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000095017025071382/tennx-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer